Richard Pops, Alkermes CEO (via Alkermes website)
July 28, 2023 10:17 AM EDTUpdated 03:14 PM
Pharma

Alk­er­mes hikes up 2023 fi­nan­cials by $425M af­ter In­ve­ga li­cense fight win against John­son & John­son

Katherine Lewin

News Reporter

Alk­er­mes is fly­ing high in­to the sec­ond half of 2023 with its up­dat­ed year­ly guid­ance, thanks in part to back roy­al­ties and in­ter­est from an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times